|  |
| --- |
| Document ID:       |

N4. Signing of power of attorney

Please note that the possibility to enter into new agreements according to the multicentre principle ends 2023-07-01 due to the entry into force of the Biobank Act (2023:38).

The addition of site (private healthcare provider) can only be done for ongoing studies. Other amendments, concerning agreements signed before 2023-07-01, are made using document N2 for research regulated by the Ethical Review Act and document T1a for clinical trials and performance studies regulated by EU regulations (CTR, MDR and IVDR). All documents can be found at biobanksverige.se/document.

For a private Healthcare provider to be part of a multicentre study handled by a Regional Biobank Centre (RBC), signing of power of attorney between the private Healthcare provider and the e-biobank of the Region where the sampling is taking place is required. The power of attorney means that the sample collection in question, together with associated personal data, is part of a sample collection in the Region’s e-biobank. Thereby, the sample collection can be released through the e-biobank to a recipient biobank in accordance with the biobank agreement.

The Principal Investigator/Sponsor is responsible for the documentation of consent and samples taken, for documenting withdrawal of consent, and for tracing samples together with other measures following withdrawal of consent.

**Please note**: For this procedure, the following applies:

For research regulated by the Ethical Review Act the Principal Investigator must be active within a region, a municipality, a university, or a college and at least one of the included clinics/sites must belong to a region.

For clinical trials regulated by EU regulations (CTR, MDR and IVDR), at least one of the included clinics/sites must belong to a region.

|  |
| --- |
| 1. Power of attorney
 |
| **Samples and personal data, collected in the operation of the Healthcare provider specified below, in stated study is established as a primary sample collection in another Principal’s e-biobank.** |
| 1.1 Study title (same as specified in the application of ethical approval):      |
| 1.2 Study working title:      |
| 1.3 Registration no. of the Swedish ethical approval (if applicable): | 1.4 Study ID (if applicable): | 1.5 EudraCT No./EU trial No. (if clinical trials of medicinal products): | 1.6 CIV-ID (if clinical investigations of medical devices): |
|       |       |       |       |
| 1.7 Healthcare provider where the samples are collected:      |
| 1.8 Principal (region) of the e-biobank where the samples are established as a primary sample collection:      |
| 1.9 Registration number of the e-biobank (issued by the Health and Social Care Inspectorate):      |
| 1.10 RBC handling the biobank agreement:      |

|  |
| --- |
| 1. Signatures
 |
| 2.1 Authorized representative of the Healthcare provider |
| 2.1.1 Date:       |
| 2.1.2 Signature:  | 2.1.3 Name in print:      |
| 2.1.4 Phone:       | 2.1.5 E-mail:       |
| 2.2 Authorized representative of the e-biobank |
| 2.2.1 Date:       |
| 2.2.2 Signature:  | 2.2.3 Name in print:      |
| 2.2.4 Phone:      | 2.2.5 E-mail:       |